https://www.nasdaq.com/press-release/aeglea-biotherapeutics-to-participate-in-two-investor-conferences-in-january-2022
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-announces-achievement-of-primary-endpoint-in-phase-3-study-of
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-to-host-conference-call-to-report-phase-3-topline-results-of
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-appoints-hunter-c.-smith-to-board-of-directors-2021-11-16
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-reports-third-quarter-2021-financial-results-and-corporate
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-announces-presentation-of-seven-abstracts-at-iciem-2021
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-to-participate-in-multiple-conferences-in-september-2021-2021
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-reports-second-quarter-2021-financial-results-and-corporate
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-appoints-jim-kastenmayer-as-general-counsel-2021-07-15
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-announces-publication-of-20-week-data-from-phase-1-2-and-open
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-appoints-jonathan-d.-alspaugh-as-chief-financial-officer-2021
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-doses-first-patient-in-a-phase-1-2-clinical-trial-of-agle-177
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-appoints-marcio-souza-to-board-of-directors-2021-06-22
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-reports-first-quarter-2021-financial-results-and-corporate
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-launches-think-argininetm-a-disease-education-initiative-to
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-completes-patient-randomization-for-peace-its-pivotal-phase-3
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-and-immedica-announce-commercialization-agreement-for
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-reports-fourth-quarter-and-full-year-2020-financial-results
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-appoints-sara-brownstein-to-board-of-directors-2021-02-24
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-announces-transition-of-chief-financial-officer-2021-02-03
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-to-present-at-39th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-appoints-alison-lawton-to-board-of-directors-2020-12-17
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-receives-fda-rare-pediatric-disease-designation-for-acn00177
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-reports-third-quarter-2020-financial-results-and-corporate
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-announces-u.s.-and-eu-orphan-drug-designations-for-acn00177
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-announces-presentations-on-arginase-1-deficiency-and
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-to-participate-in-september-investment-conferences-2020-09-02
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-to-present-at-world-orphan-drug-congress-usa-2020-2020-08-18
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-reports-second-quarter-2020-financial-results-and-corporate
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-to-present-at-bio-digital-2020-2020-06-01
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-announces-change-of-location-of-annual-meeting-of-stockholders
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-announces-1-year-data-for-pegzilarginase-in-patients-with
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-to-present-late-breaking-1-year-data-for-pegzilarginase-in
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-reports-first-quarter-2020-financial-results-and-corporate
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-announces-closing-of-public-offering-and-full-exercise-of
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-announces-pricing-of-%24120-million-public-offering-2020-04-28
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-announces-proposed-public-offering-2020-04-27
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-announces-approval-of-clinical-trial-application-for-its-novel
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-reports-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-submits-cta-application-for-its-novel-engineered-human-enzyme
https://www.nasdaq.com/press-release/aeglea-biotherapeutics-to-present-at-38th-annual-j.p.-morgan-healthcare-conference
